Trial intelligence / Profile preview

Saxagliptin Monotherapy with Titration in Type 2 Diabetes

NCT00316082Phase 3Completed

Sponsor
AstraZeneca
Start
Jun 2006
Primary completion
Nov 2007
Modality
Small Molecules
Countries
4
01

Overview

A Phase 3 trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Jun 2006; status: completed.

02

Drugs

saxagliptin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT00316082.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00316082.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call